{"id":31753,"date":"2021-09-16T00:00:46","date_gmt":"2021-09-16T07:00:46","guid":{"rendered":"https:\/\/vermont.salk.edu\/?post_type=disclosure&p=31753"},"modified":"2021-10-18T09:23:56","modified_gmt":"2021-10-18T16:23:56","slug":"the-salk-institute-and-sanford-burnham-prebys-licensed-ulk1-2-inhibitors-to-endeavor-biomedicines-for-treatment-of-cancer","status":"publish","type":"disclosure","link":"https:\/\/www.salk.edu\/es\/news-release\/the-salk-institute-and-sanford-burnham-prebys-licensed-ulk1-2-inhibitors-to-endeavor-biomedicines-for-treatment-of-cancer\/","title":{"rendered":"El Instituto Salk y Sanford Burnham Prebys otorgan licencia de inhibidores de ULK1\/2 a Endeavor BioMedicines para el tratamiento del c\u00e1ncer"},"content":{"rendered":"

LA JOLLA\u2014El Instituto Salk, junto con Sanford Burnham Prebys, han firmado un acuerdo de licencia exclusiva con Endeavor BioMedicines, con sede en California, para una cartera de propiedad intelectual relacionada con terapias y diagn\u00f3sticos de c\u00e1ncer dirigidos a ULK1\/2, una prote\u00edna involucrada en el reciclaje celular, desarrollada conjuntamente por investigadores de Salk y Sanford Burnham Prebys. Las negociaciones fueron dirigidas por la Oficina de Desarrollo Tecnol\u00f3gico de Salk y la Oficina de Desarrollo de Negocios de Sanford Burnham Prebys.<\/p>\n

\u201cThis line of anti-cancer research has the potential to have a significant impact for patients,\u201d says Reuben Shaw<\/a>, director of the Salk NCI-Designated Cancer Center<\/a>, professor in Salk\u2019s Molecular and Cell Biology Laboratory and the William R. Brody Chair. \u201cWe are thrilled that the benefits of our approach are being realized with this clinically important licensing agreement.\u201d<\/p>\n

In 2015, Shaw and his colleagues at Salk, working with Nicholas Cosford, professor and deputy director of the NCI-Designated Cancer Center at Sanford Burnham Prebys, demonstrated that by chemically blocking ULK1<\/a>\/2, they could shut down the cellular recycling pathway known as autophagy that some cancer cells use to stay alive. Autophagy breaks down unneeded or damaged cellular components into their building blocks to use for new cellular parts, which is critical for cells that are growing rapidly and don\u2019t have enough nutrient supply, as do many cancers. The researchers found small molecule compounds that effectively blocked ULK1\/2 and killed cancer cells, including human and mouse lung cancer cells and human pancreatic cancer cells.<\/p>\n

\u201cSince we initially discovered how cancer cells starved of nutrients activate ULK1\/2, we focused on finding a drug that could block its activity,\u201d says Cosford. \u201cUsing medicinal chemistry, chemical biology and rational drug design we have created this compound and are hopeful it will have an impact as an anti-cancer treatment. This agreement with Endeavor BioMedicines moves our efforts closer to helping people living with cancer.\u201d<\/p>\n

Over the better part of a decade, Salk and Sanford Burnham Prebys scientists collaborated to perform the early-stage research needed to translate their initial findings about ULK1\/2 into improved drug candidates and clinically actionable observations to which cancers are most likely to respond. Inhibition of autophagy has emerged from a number of different research labs in the last few years as an excellent way to overcome therapeutic resistance to both chemotherapies and targeted therapies, and more recently in certain cases of immunotherapy resistance, as well.<\/p>\n

Under the license agreement, Endeavor gains worldwide, exclusive rights to Salk and Sanford Burnham Prebys\u2019 intellectual property of drug candidates, including a lead ULK1\/2 inhibitor molecule that has now been through extensive preclinical and toxicity studies, as well as biomarkers that can help clinicians determine which cancer patients are most likely to benefit from drugs targeting ULK1\/2. Endeavor plans to complete IND-enabling studies and advance the program into the clinic, initially in colorectal and lung cancers, in the next 18 months.<\/p>\n

Acerca del Instituto Salk de Estudios Biol\u00f3gicos<\/strong>
\nCada cura tiene un punto de partida. El Instituto Salk encarna la misi\u00f3n de Jonas Salk de atreverse a convertir los sue\u00f1os en realidad. Sus cient\u00edficos, de renombre internacional y galardonados, exploran los cimientos mismos de la vida, buscando nuevas comprensiones en neurociencia, gen\u00e9tica, inmunolog\u00eda, biolog\u00eda vegetal y m\u00e1s. El Instituto es una organizaci\u00f3n independiente sin fines de lucro y un hito arquitect\u00f3nico: peque\u00f1o por elecci\u00f3n, \u00edntimo por naturaleza e intr\u00e9pido ante cualquier desaf\u00edo. Ya sea c\u00e1ncer o Alzheimer, envejecimiento o diabetes, el Instituto Salk es donde comienzan las curas. Obtenga m\u00e1s informaci\u00f3n en: salk.edu.<\/p>\n

About Sanford Burnham Prebys Medical Discovery Institute<\/strong>
\nSanford Burnham Prebys is a preeminent, independent biomedical research institute dedicated to understanding human biology and disease and advancing scientific discoveries to profoundly impact human health. For more than 40 years, our research has produced breakthroughs in cancer, neuroscience, immunology and children\u2019s diseases, and is anchored by our NCI-designated Cancer Center and advanced drug discovery capabilities. For more information, visit us at\u00a0SBPdiscovery.org<\/a>\u00a0or on Facebook at\u00a0facebook.com\/SBPdiscovery<\/a>\u00a0and on Twitter\u00a0@SBPdiscovery<\/a>.<\/p>\n

About Endeavor BioMedicines<\/strong>
\nEndeavor BioMedicines is a clinical-stage precision medicine company targeting the core drivers of multiple terminal diseases, including oncology and fibrosis. We combine advancements in technology with evolving understanding of terminal diseases to develop best-in-class medicines with the potential to reverse the most severe health conditions. Our lead program, ENV-101, is a Hedgehog signaling inhibitor with proven clinical activity that we are investigating in multiple cancers and in idiopathic pulmonary fibrosis. At Endeavor, we are a highly qualified, innovative and focused team that has come together to live up to our name and bold mission: to help patients feel better and live longer. Endeavor is supported by leading investors Omega Funds and Longitude Capital. More information is available at www.endeavorbiomedicines.com<\/a>.\u00a0<\/strong><\/p>","protected":false},"featured_media":0,"template":"","faculty":[45],"disease-research":[46],"class_list":["post-31753","disclosure","type-disclosure","status-publish","hentry","faculty-reuben-shaw","disease-research-cancer-biology"],"acf":[],"yoast_head":"\nThe Salk Institute and Sanford Burnham Prebys license ULK1\/2 inhibitors to Endeavor BioMedicines for treatment of cancer - Salk Institute for Biological Studies<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.salk.edu\/es\/news-release\/the-salk-institute-and-sanford-burnham-prebys-licensed-ulk1-2-inhibitors-to-endeavor-biomedicines-for-treatment-of-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Salk Institute and Sanford Burnham Prebys license ULK1\/2 inhibitors to Endeavor BioMedicines for treatment of cancer - Salk Institute for Biological Studies\" \/>\n<meta property=\"og:description\" content=\"LA JOLLA\u2014The Salk Institute, along with Sanford Burnham Prebys, have signed an exclusive licensing agreement with California-based Endeavor BioMedicines for an intellectual property portfolio relating to cancer therapeutics and diagnostics that target ULK1\/2, a protein involved in cellular recycling, jointly developed by researchers at Salk and Sanford Burnham Prebys. The negotiations were led by the Salk Office of Technology Development and the Sanford Burnham Prebys Business Development Office.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.salk.edu\/es\/news-release\/the-salk-institute-and-sanford-burnham-prebys-licensed-ulk1-2-inhibitors-to-endeavor-biomedicines-for-treatment-of-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Salk Institute for Biological Studies\" \/>\n<meta property=\"article:modified_time\" content=\"2021-10-18T16:23:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2023\/03\/salk-institute-preview-image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"628\" \/>\n\t<meta property=\"og:image:height\" content=\"329\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/the-salk-institute-and-sanford-burnham-prebys-licensed-ulk1-2-inhibitors-to-endeavor-biomedicines-for-treatment-of-cancer\\\/\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/the-salk-institute-and-sanford-burnham-prebys-licensed-ulk1-2-inhibitors-to-endeavor-biomedicines-for-treatment-of-cancer\\\/\",\"name\":\"The Salk Institute and Sanford Burnham Prebys license ULK1\\\/2 inhibitors to Endeavor BioMedicines for treatment of cancer - Salk Institute for Biological Studies\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#website\"},\"datePublished\":\"2021-09-16T07:00:46+00:00\",\"dateModified\":\"2021-10-18T16:23:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/the-salk-institute-and-sanford-burnham-prebys-licensed-ulk1-2-inhibitors-to-endeavor-biomedicines-for-treatment-of-cancer\\\/#breadcrumb\"},\"inLanguage\":\"es-MX\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/the-salk-institute-and-sanford-burnham-prebys-licensed-ulk1-2-inhibitors-to-endeavor-biomedicines-for-treatment-of-cancer\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/the-salk-institute-and-sanford-burnham-prebys-licensed-ulk1-2-inhibitors-to-endeavor-biomedicines-for-treatment-of-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.salk.edu\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Salk Institute and Sanford Burnham Prebys license ULK1\\\/2 inhibitors to Endeavor BioMedicines for treatment of cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#website\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/\",\"name\":\"Salk Institute for Biological Studies\",\"description\":\"The Power of Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.salk.edu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es-MX\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#organization\",\"name\":\"Salk Institute for Biological Studies\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es-MX\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/salk_logo_696.jpg\",\"contentUrl\":\"http:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/salk_logo_696.jpg\",\"width\":696,\"height\":696,\"caption\":\"Salk Institute for Biological Studies\"},\"image\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The Salk Institute and Sanford Burnham Prebys license ULK1\/2 inhibitors to Endeavor BioMedicines for treatment of cancer - Salk Institute for Biological Studies","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.salk.edu\/es\/news-release\/the-salk-institute-and-sanford-burnham-prebys-licensed-ulk1-2-inhibitors-to-endeavor-biomedicines-for-treatment-of-cancer\/","og_locale":"es_MX","og_type":"article","og_title":"The Salk Institute and Sanford Burnham Prebys license ULK1\/2 inhibitors to Endeavor BioMedicines for treatment of cancer - Salk Institute for Biological Studies","og_description":"LA JOLLA\u2014The Salk Institute, along with Sanford Burnham Prebys, have signed an exclusive licensing agreement with California-based Endeavor BioMedicines for an intellectual property portfolio relating to cancer therapeutics and diagnostics that target ULK1\/2, a protein involved in cellular recycling, jointly developed by researchers at Salk and Sanford Burnham Prebys. The negotiations were led by the Salk Office of Technology Development and the Sanford Burnham Prebys Business Development Office.","og_url":"https:\/\/www.salk.edu\/es\/news-release\/the-salk-institute-and-sanford-burnham-prebys-licensed-ulk1-2-inhibitors-to-endeavor-biomedicines-for-treatment-of-cancer\/","og_site_name":"Salk Institute for Biological Studies","article_modified_time":"2021-10-18T16:23:56+00:00","og_image":[{"width":628,"height":329,"url":"https:\/\/www.salk.edu\/wp-content\/uploads\/2023\/03\/salk-institute-preview-image.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.salk.edu\/news-release\/the-salk-institute-and-sanford-burnham-prebys-licensed-ulk1-2-inhibitors-to-endeavor-biomedicines-for-treatment-of-cancer\/","url":"https:\/\/www.salk.edu\/news-release\/the-salk-institute-and-sanford-burnham-prebys-licensed-ulk1-2-inhibitors-to-endeavor-biomedicines-for-treatment-of-cancer\/","name":"The Salk Institute and Sanford Burnham Prebys license ULK1\/2 inhibitors to Endeavor BioMedicines for treatment of cancer - Salk Institute for Biological Studies","isPartOf":{"@id":"https:\/\/www.salk.edu\/#website"},"datePublished":"2021-09-16T07:00:46+00:00","dateModified":"2021-10-18T16:23:56+00:00","breadcrumb":{"@id":"https:\/\/www.salk.edu\/news-release\/the-salk-institute-and-sanford-burnham-prebys-licensed-ulk1-2-inhibitors-to-endeavor-biomedicines-for-treatment-of-cancer\/#breadcrumb"},"inLanguage":"es-MX","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.salk.edu\/news-release\/the-salk-institute-and-sanford-burnham-prebys-licensed-ulk1-2-inhibitors-to-endeavor-biomedicines-for-treatment-of-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.salk.edu\/news-release\/the-salk-institute-and-sanford-burnham-prebys-licensed-ulk1-2-inhibitors-to-endeavor-biomedicines-for-treatment-of-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.salk.edu\/"},{"@type":"ListItem","position":2,"name":"The Salk Institute and Sanford Burnham Prebys license ULK1\/2 inhibitors to Endeavor BioMedicines for treatment of cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.salk.edu\/#website","url":"https:\/\/www.salk.edu\/","name":"Instituto Salk de Estudios Biol\u00f3gicos","description":"El Poder de la Ciencia","publisher":{"@id":"https:\/\/www.salk.edu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.salk.edu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es-MX"},{"@type":"Organization","@id":"https:\/\/www.salk.edu\/#organization","name":"Instituto Salk de Estudios Biol\u00f3gicos","url":"https:\/\/www.salk.edu\/","logo":{"@type":"ImageObject","inLanguage":"es-MX","@id":"https:\/\/www.salk.edu\/#\/schema\/logo\/image\/","url":"http:\/\/www.salk.edu\/wp-content\/uploads\/2023\/03\/salk_logo_696.jpg","contentUrl":"http:\/\/www.salk.edu\/wp-content\/uploads\/2023\/03\/salk_logo_696.jpg","width":696,"height":696,"caption":"Salk Institute for Biological Studies"},"image":{"@id":"https:\/\/www.salk.edu\/#\/schema\/logo\/image\/"}}]}},"ACF":{"paper_url":"","journal_title":"","paper_author_list":"","doi":"","paper_title":"","subhead":"","home_photo":"","listing_photo":"","legacy_boilerplate":[],"hide_boilerplate":["Hide"],"disable_date":false,"listing_excerpt":"","descriptive_blurb":"","has_journal_cover":false,"og_image_override":false,"gallery":false},"_links":{"self":[{"href":"https:\/\/www.salk.edu\/es\/wp-json\/wp\/v2\/disclosure\/31753","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.salk.edu\/es\/wp-json\/wp\/v2\/disclosure"}],"about":[{"href":"https:\/\/www.salk.edu\/es\/wp-json\/wp\/v2\/types\/disclosure"}],"version-history":[{"count":4,"href":"https:\/\/www.salk.edu\/es\/wp-json\/wp\/v2\/disclosure\/31753\/revisions"}],"predecessor-version":[{"id":32043,"href":"https:\/\/www.salk.edu\/es\/wp-json\/wp\/v2\/disclosure\/31753\/revisions\/32043"}],"wp:attachment":[{"href":"https:\/\/www.salk.edu\/es\/wp-json\/wp\/v2\/media?parent=31753"}],"wp:term":[{"taxonomy":"faculty","embeddable":true,"href":"https:\/\/www.salk.edu\/es\/wp-json\/wp\/v2\/faculty?post=31753"},{"taxonomy":"disease-research","embeddable":true,"href":"https:\/\/www.salk.edu\/es\/wp-json\/wp\/v2\/disease-research?post=31753"}],"curies":[{"name":"la hora de","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}